Galapagos increases share capital through subscription right exercises
Mechelen, Belgium; 20 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
Galapagos issued 80,290 new ordinary shares on 20 June 2022, for a total capital increase (including issuance premium) of EUR 1,459,506.60.
Pursuant to the subscription right exercise program for Galapagos’ executive committee, the members of the executive committee automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, one executive committee member exercised 5,000 subscription rights.
In accordance with Belgian transparency legislation1, Galapagos also wishes to note that its total share capital currently amounts to EUR 355,533,029.01, the total number of securities conferring voting rights amounts to 65,728,511, which is also the total number of voting rights (the denominator), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (formerly known as ‘warrants’) to subscribe to not yet issued securities conferring voting rights is (i) 9,060,766 subscription rights under several outstanding personnel subscription right plans, which equals 9,060,766 voting rights that may result from the exercise of those subscription rights, and (ii) 1 subscription right issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead (and its affiliated companies) to 29.9% of the actually issued and outstanding shares after the exercise of such subscription right. The foregoing excludes the 2,326,025 subscription rights of Subscription Right Plan 2022 BE, Subscription Right Plan 2022 RMV and Subscription Right Plan 2022 ROW, which were created subject to acceptance. Galapagos does not have any convertible bonds or shares without voting rights outstanding.
Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at www.glpg.com.
Sofie Van Gijsel
Head of Investor Relations
+1 781 296 1143
Director Investor Relations
+32 495 58 46 63
Head of Corporate Communication
+32 479 490 603
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.
1Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (as amended from time to time).
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy30.6.2022 10:00:00 CEST | Press release
First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal squamous cell carcinoma1 Statistically significant survival benefit with tislelizumab plus chemotherapy was observed regardless of PD-L1 status and consistent across all patient subgroups1 Novartis to discuss results of multi-regional RATIONALE 306 study, the seventh positive Phase III trial readout for tislelizumab, with regulatory health authorities Basel, June 30, 2022 — Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 m
PRE ANNOUNCEMENT OF CERTIFICATE AUCTION TENDER30.6.2022 09:31:00 CEST | Press release
PRE ANNOUNCEMENT OF CERTIFICATE AUCTION TENDER MONETARY POLICY MEETING 2022-06-29 AUCTION PERIODS COMMENCING: 2022-07-06: FIXED RATE 0.75 % (VALID UNTIL NEXT MONETARY POLICY MEETING) DEPOSIT RATE 0.65 % LENDING RATE 0.85 %
Huhtamaki publishes 2022 Half-yearly Report on July 21, 202230.6.2022 09:00:00 CEST | Press release
HUHTAMÄKI OYJ PRESS RELEASE 30.6.2022 AT 10:00 Huhtamaki publishes 2022 Half-yearly Reporton July21, 2022 Huhtamäki Oyj will publish its 2022 Half-yearly Report on Thursday, July 21, 2022, approximately at 8.30 am Finnish time (EEST). The release and related results presentation material will be available after publishing at www.huhtamaki.com/investors. Teleconference Huhtamaki will arrange a combined audiocast and teleconference on the same day at 9.30 am Finnish time, where the company’s management will present the results. The event will be followed by a Q&A session. The event will be held in English, it can be followed real-time at: https://huhtamaki.videosync.fi/2022-q2 If you wish to ask questions, please dial one of the following numbers 5-10 minutes prior to the call start: Finland Toll: +358981710310 Sweden Toll: +46 856642651 United Kingdom Toll: +44 3333000804 United States Toll: +1 6319131422 Confirmation code for the call is 23337170# An on-demand replay of the audiocast w
Fingerprints announces design win for its optical under-display solution with major Asian smartphone OEM30.6.2022 08:00:00 CEST | Press release
Fingerprint Cards AB (Fingerprints™) today announced that it has secured a design win* for its optical under-display solution, FPC 1632, with a major Asian smartphone OEM, following successful qualification tests earlier this year. We expect to commence shipments during the fourth quarter of 2022. “Since many years, Fingerprints is a well-established world leader in capacitive fingerprint sensors. The design win we are announcing today marks our entry into a new market segment: optical under-display fingerprint sensors. This will open up attractive new growth opportunities for us going forward, and our goal is to capture a significant share of this market,” says Ted Hansson, President Mobile, PC & Access China at Fingerprints. For more information about Fingerprints’ mobile device solutions, visit the website. * Fingerprints’ definition of Design Win (DW): The decision by a device vendor (OEM or ODM) to start development of one or several commercial product(s) incorporating Fingerprint
Inaugural Yara Clean Ammonia Capital Markets Day30.6.2022 08:00:00 CEST | Press release
Oslo, 30 June 2022: Today, Yara International ASA (“Yara”) will host a Capital Markets Day (“CMD”) for Yara Clean Ammonia (“YCA” or the “Company”). During the event, members of YCA’s management team will present key features of the Company, including its strategy and growth ambitions, as well as financial parameters and targets for the future. In May 2022, Yara announced that it is evaluating a potential initial public offering (“IPO”) of YCA on the Oslo Stock Exchange. “While the decision to list YCA will be made in due course, Yara is now excited to host an inaugural CMD for YCA to showcase their exciting story,” said Svein Tore Holsether, CEO and President of Yara. “YCA combines a leading midstream business with exceptional growth prospects and a value creating project portfolio.” Key highlights: Clean ammonia represents a massive opportunity that is projected to drive exponential, long-term market growth .YCA comprises existing cash flows from a market leading position  in a